In vitro 実験系による肺がん化学療法レジメンの抗腫瘍効果の評価
In vitro 実験系による肺がん化学療法レジメンの抗腫瘍効果の評価
复制标题
体外实验系统评价肺癌化疗方案的抗肿瘤效果
DOI：
--
复制
发表时间：
2010
期刊：
影响因子：
--
通讯作者：
健 井関
中科院分区：
文献类型：
--
作者：
斎藤 由起子;剛 平野;洋充 沖;笠師 久美子;満 菅原;正紀 小林;夏子 高橋;史郎 板垣;健 井関
肺癌是癌症死亡的主要原因。肺癌的治疗方法主要有手术、化疗、放疗3种。大多数情况下，化疗是首选，以顺铂为基础的联合治疗在肺癌化疗中起主要作用。由于肺癌化疗方案的抗癌效果尚未进行体外评价，因此我们评价了顺铂和伊立替康联合治疗（IP治疗）和顺铂和依托泊苷联合治疗（EP治疗）的效果。治疗），使用3-（4,5-二甲基噻唑-2-基）-2,5-二苯基溴化四唑（MTT）测定人肺腺癌A 549上皮细胞系细胞。在MTT测定中，按照与方案相同的时间表添加药物溶液。药物的暴露时间是它们的半衰期，药物浓度是半衰期的IC50值。我们的结果表明：顺铂比伊立替康和依托泊苷具有更强的抗增殖作用，并且所有药物都具有很强的抗癌作用。研究表明，在这些联合治疗中，这些药物一起比单独给药时具有更强的抗癌作用。对于IP治疗，细胞活力在第28天恢复，而对于EP治疗，细胞活力在第15天恢复。这些结果表明MTT测定可以在体外用于评估癌症化疗方案以及剂量IP 治疗和 EP 治疗的时间表。
Lung cancer is the leading cause of cancer mortality.There are 3 major types of lung cancer therapy-surgery,chemotherapy and radiotherapy.In most cases,chemotherapy is the first choice and cisplatin-based combination therapy plays a major role in lung cancer chemotherapy.As the anticancer effects of lung cancer chemotherapy regimens have not been evaluated in vitro ,we evaluated the effects of combination therapy with cisplatin and irinotecan (IP therapy) and that with cisplatin and etoposide (EP therapy),using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay in human lung adenocarcinoma A 549 epithelial cell line cells.In the MTT assay,drug solutions were added according to the same schedule as for the regimens.The exposure times of the drugs were their half-lives,and drug concentrations were the IC50 values of the half-lives.Our results suggested that cisplatin had a much stronger antiproliferative effect than irinotecan and etoposide,and that all agents had a strong anticancer effect.It has been shown that in these combination therapies,together,the drugs have a stronger anticancer effect than they do when given alone.For IP therapy,cell viability returned at day 28,while it returned at day 15 for EP therapy.These results suggested that the MTT assay can be used in vitro to evaluate cancer chemotherapy regimens as well as dosing schedules for IP therapy and EP therapy.
DOI：
--
发表时间：
1998-05
期刊：
Clinical cancer research : an official journal of the American Association for Cancer Research
影响因子：
--
作者：
P. Bunn;K. Kelly
通讯作者：
P. Bunn;K. Kelly